Search
for

    Sort by

    Research 511–540 of 1000+

    1. Tratamento de alopecia androgenética (AAG) masculina com extrato de chá verde (Camellia Sinensis) com ênfase no ativo epigalocatequina galato 3 2019
    2. Synthesis, Biological Evaluation and in silico Studies of Novel 5α-aza-Bhomo-3,5-secosteroids as Potential 5-reductase Inhibitors Letters in Drug Design & Discovery · 2016
    3. Posters Presented at the 19th Joint Meeting of the International Society of Dermatopathology, March 2–3, 2016, Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia, USA American Journal of Dermatopathology · 2016
    4. インタビュー 内井乃生夫人に聞く 宮崎台ビレジに見る建築家内井昭蔵の姿勢 (39年の時を経た名建築に住む 宮崎台ビレジ--設計=内井昭蔵建築設計事務所) 住宅建築 · 2010
    5. 任意方向の負荷に対する多自由度機構の出力変位誤差評価 : 評価法の提案と3自由度空間パラレルメカニズムの高剛性化(機械力学,計測,自動制御) 日本機械学會論文集. C編 · 2005
    6. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial The Lancet · 2023 · 227 citations
    7. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone. Biochemical Pharmacology · 2001 · 22 citations
    8. Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials 2018 · 21 citations
    9. New case of trichorinophalangeal syndrome-like phenotype with a de novo t(2;8)(p16.1;q23.3) translocation which does not disrupt the TRPS1 gene BMC medical genetics · 2014 · 9 citations
    10. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial Journal of the American Academy of Dermatology · 2024 · 7 citations
    11. Pharmacokinetic Interaction of Finasteride With Tamsulosin Hydrochloride: An Open-label, Randomized, 3-period Crossover Study in Healthy Chinese Male Volunteers Clinical Therapeutics · 2014 · 7 citations
    12. Involucrin, but not filaggrin and Kdap mRNA, expression is downregulated in 3-D cultures of intact rat hair bulbs after calcium stimulation Folia Histochemica et Cytobiologica · 2011 · 3 citations
    13. 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure Journal of the American Academy of Dermatology · 2023 · 2 citations
    14. Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata” Journal of the American Academy of Dermatology · 2025 · 1 citations
    15. Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies SKIN The Journal of Cutaneous Medicine · 2023 · 1 citations
    16. 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study Journal of The American Academy of Dermatology · 2021 · 1 citations
    17. 74643 Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials Journal of the American Academy of Dermatology · 2026
    18. 75810 Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program Journal of the American Academy of Dermatology · 2026
    19. 75893 Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials Journal of the American Academy of Dermatology · 2026
    20. 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials Journal of the American Academy of Dermatology · 2026
    21. Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’ Journal of the European Academy of Dermatology and Venereology · 2025
    22. Pengaruh Ekstrak Metanol Batang Etlingera alba (Blume) A. D. Poulsen Terhadap Penekanan Genicaspase-3 sebagai Penanda Apoptosis pada Lini Sel Kanker Payudara T47D Secara In Vitro Jurnal Mandala Pharmacon Indonesia · 2025
    23. 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study Journal of Investigative Dermatology · 2025
    24. 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials Journal of the American Academy of Dermatology · 2024
    25. Faculty Opinions recommendation of Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3-arm, pilot trial. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2023
    26. Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3‐arm, pilot trial Journal of Cosmetic Dermatology · 2023
    27. 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA) Journal of the American Academy of Dermatology · 2023
    28. Referee report. For: Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment [version 3; peer review: 2 approved] Faculty of 1000 Research Ltd · 2021
    29. 금잔화, 상황, 어성초 에탄올 추출물의 세포독성 평가 및 3T3-L1 세포에 대한 육모 효과 한국약용작물학회지 · 2017
    30. Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis Journal of The American Academy of Dermatology · 2016